Drug Search Results
More Filters [+]

CKD-397

Alternative Names: ckd-397, ckd397, ckd 397
Latest Update: 2017-08-09
Latest Update Note: Clinical Trial Update

Product Description

Chong Kun Dang was developing ckd-397, an oral ADRA1A agonist,PDE5 Inhibitor, for the treatment of Benign Prostatic Hypertrophy (BPH) (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02615782)

Mechanisms of Action: ADRA1A agonist,PDE5 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Chong Kun Dang
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CKD-397

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Prostatic Hyperplasia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

150FDI15031

P1

Completed

Prostatic Hyperplasia

2016-04-01

Recent News Events

Date

Type

Title